Skip to content

PAR-25-164 NIDCR genomics data R01 eligibility Guide

Updated 5 official sources

Quick Answer: PAR-25-164 was an NIDCR R01 for projects using existing genomic data to answer dental, oral, and craniofacial research questions. NIH marks it expired as of May 8, 2026.

Full answer and how we checked it

It was clinical trial not allowed, had a May 7, 2026 last listed AIDS due date, allowed up to 3 project years, and remains useful as a route model for future NIDCR existing-data work. The 2026 decision turns on 7 checks.

Who this is for: Dental, oral, craniofacial, genomic medicine, bioinformatics, biostatistics, and sponsored-research teams deciding whether an existing-data R01 was the right model and what to prepare for the next NIDCR route.

Data note: This guide uses NIH PAR-25-164, companion PAR-25-166, Grants.gov listing 357212, and USAspending.gov FY2024 award records, checked again on October 10, 2026.

In this guide

Quick Facts

Agency
HHS
Last deadline
May 7, 2026 (passed)
Status
Closed

Assistance Listing 93.121: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.121, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
1,951
Avg Award (whole listing)
$2,735,109
Median Award (whole listing)
$1,097,670
Total Funding (FY2024, whole listing)
$379.1M
YoY Funding Trend
-0.3%

Data last verified: May 21, 2026

PAR-25-164 is not a general secondary-data R01. NIH frames it around research questions relevant to human dental, oral, and craniofacial biology, diseases, and conditions. The project must use existing genomic data with statistical or computational analysis, and it should include validation of results or validation of a newly developed analytic method.

The practical question is simple: can the team name the DOC research question, the public data assets, the genomic analysis plan, and the validation endpoint before drafting the Specific Aims page?

Use this guide with the live NIDCR Existing Genomics Data R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Substance Use Existing Data R21 guide, NEI Secondary Data R21 guide, and the Grantsights grant database.

October 2026 Source Check

As of October 10, 2026, NIH marks PAR-25-164 as expired. The last listed AIDS due date was May 7, 2026, and the expiration date was May 8, 2026. NIH also marks companion R03 PAR-25-166 expired, so applicants should use both notices as source history unless NIH posts a reissue.

Source factOctober 2026 answer
Funding numberPAR-25-164
ActivityR01 Research Project Grant
Clinical trial statusNot allowed
Budget ruleNot limited, but tied to actual project need
Project periodUp to 3 years
Companion routePAR-25-166 R03, also expired

The source check changes the above-the-fold answer. It should help teams decide whether their DOC genomics idea fits the expired route logic, a possible reissue, parent R01, parent R03, R21, SBIR/STTR, or another NIDCR route.

7 PAR-25-164 Eligibility Stop Checks

Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.

7 stop checks decide whether this route makes sense. The core pattern is not "we have data." It is "we have a DOC question that can be answered with existing genomic data and checked with a validation plan."

Stop checkStrong R01 signalRed flag
DOC relevanceDental, oral, or craniofacial question is centralGeneral genomics with a thin DOC mention
Data sourceExisting genomic data are namedData access is uncertain
Public sharingPublicly shared data are used when possibleCore data cannot be shared and has weak justification
Analysis planStatistical or computational plan is matched to the questionTool choice leads the science
ValidationExperimental or in silico validation is plannedFindings end at association only
Trial statusNo NIH-defined clinical trialHuman intervention assignment is planned
MechanismR01 scale is neededProject is really an R03 or R21

The route is strongest when the applicant can explain why the selected data can answer a DOC question better than a new small cohort would.

5 Source Facts Applicants Should Know

Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.

5 facts should appear early in a public page. NIH lists PAR-25-164 as an R01 Research Project Grant, clinical trial not allowed, with assistance listing 93.121. NIH also lists companion R03 PAR-25-166.

FactSource-backed read
Funding numberPAR-25-164
MechanismR01 Research Project Grant
Clinical trial statusNot allowed
Last listed due dateMay 7, 2026
ExpirationMay 8, 2026

NIH says application budgets were not limited but had to reflect the actual needs of the project. According to USAspending.gov (opens in a new tab) data, assistance listing 93.121 had about $379.1M in FY2024 obligations across 1,951 awards active that year.

What NIH Doesn't Tell You

Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.

First, the existing data must be more than convenient. Reviewers will ask whether the data source, quality, variables, metadata, consent, and missingness can support the DOC claim.

Second, genomic data must be central. NIH names whole exome, whole genome, transcriptomic, epigenomic, single-cell, metagenomic, and related data types as possible examples. Complementary data can help, but genomic analysis cannot be a side note.

Third, validation needs to be real. A project that ends with a model output and no confirmatory logic may look incomplete.

Fourth, expired status matters. PAR-25-164 should be described honestly as closed. Searchers still need the route analysis because they may be preparing for a reissue, a companion route, or a similar NIDCR application.

6 Data Assets That Make This R01 Stronger

Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.

6 data assets improve fit. The first is a named genomic data source, such as FaceBase, dbGaP, Kids First, GDC, All of Us, NIMH Data Archive, or another source that fits the question.

The second is DOC-specific phenotypic context. The proposal should connect the genomic signal to oral, craniofacial, dental, pain, developmental, microbial, or related biology.

The third is a data-quality table. It should include access status, sample size, variables, assay type, missingness, ancestry or population issues, consent limits, and harmonization needs.

The fourth is a reproducibility plan. Existing data can produce fragile findings if the project does not state how results will be checked.

The fifth is a validation plan. For example, a craniofacial development team could pair public transcriptomic data with in silico validation, then use a small laboratory validation step to check the strongest signal.

The sixth is a sharing plan. NIH expects data management and sharing planning, and this route is built around public data reuse. The applicant should not postpone the sharing discussion.

5 Route Choices Before Drafting

Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.

5 route choices should be compared before a team drafts a full R01.

RouteBetter first read when...Why
PAR-25-164 modelDOC genomic analysis needs R01 scaleRoute logic fits
PAR-25-166 R03Project is smaller or method-limitedCompanion route may fit
Parent R01DOC-specific data-reuse route is closedActive route may be needed
NIDCR clinical routeHuman intervention is centralPAR-25-164 disallows trials
Institute-specific data routeDOC relevance is not centralAnother NIH institute may fit better

The strongest page answer is honest: this exact route is expired, but its fit logic remains useful for reissue planning and adjacent NIH data routes.

6 Bad-Fit Signals

Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.

6 bad-fit signals should stop a team before submission. First, the project does not include genomic data analysis. NIH explicitly says projects without genomic analysis are not recommended.

Second, the project does not use public or publicly shareable data and cannot justify why. Third, the DOC link is thin. Fourth, validation is missing. Fifth, a clinical trial is planned. Sixth, the work is too small for an R01 and should be framed as a smaller mechanism.

Those stop checks improve user trust because the page does not pretend every applicant belongs here.

21-Day Existing-Data Readiness Plan

Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.

Days 1 through 3 should confirm source status, deadline, clinical-trial status, and active-route alternatives.

Days 4 through 7 should define the DOC research question and list all candidate data sources. The team should include why each source can answer the question.

Days 8 through 12 should build a data-readiness table covering access, variables, sample size, assay type, missingness, consent, and harmonization.

Days 13 through 16 should define the validation strategy. A reviewer should be able to see what success and failure mean.

Days 17 through 21 should compare route choice. If the project is R01 scale, prepare the program-staff memo. If not, move to R03, parent R21, parent R01, or pause.

7 Above-the-Fold Claims That Need Proof

Within 21 days, the first screen should prove 7 claims: what the route funds, whether the source is open or expired, whether clinical trials are allowed, what budget rule applies, who is eligible in practice, what does not fit, and what route should be compared next. We're not trying to out-rank NIH by sounding broader.

According to NIH in the NOFO (opens in a new tab), this source should be treated as the authority for rules.

7 Route Checks Added June 2, 2026

Rechecked on October 10, 2026 against PAR-25-164 (opens in a new tab), PAR-25-166 (opens in a new tab), the Grants.gov listing (opens in a new tab), and USASpending.gov (opens in a new tab).

CheckPublic answer
EligibilityConfirm the applicant, institution, and route rules for PAR-25-164 NIDCR genomics data R01 eligibility.
Source statusVerify the official listing, notices, due date, and expiration status.
BudgetCheck award size, cost limits, match, or budget logic when the source provides it.
EvidenceName the data, preliminary work, partner role, or implementation proof needed.
Bad fitStop if the project belongs in a nearby NIDCR or federal route.
Review criteriaTie the first page to significance, approach, team, environment, and source-specific criteria.
Next actionDecide whether to draft, ask a program contact, redirect, or move to a nearby route.

According to official source 3 (opens in a new tab), the source record should be checked again when the team builds the final submission calendar.

Final public checklist

  • Confirm whether R01 is the right route or whether a nearby program fits better.
  • Check budget, partner, match, or data-readiness constraints.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 1,951 Assistance Listing records | Avg: $2.7M

REAL DATA
1

Fred Hutchinson Cancer Center

WA

$429.4M
2

President and Fellows of Harvard College

MA

$88.3M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-25-164 fund?

It supports R01 projects that answer dental, oral, or craniofacial research questions through analysis of existing genomic data and related public data.

Are clinical trials allowed?

No. PAR-25-164 is clinical trial not allowed.

Is the opportunity still open?

NIH marks PAR-25-164 expired after May 8, 2026, and Grantsights records the last listed deadline as May 7, 2026.

What is the strongest fit signal?

A strong fit uses existing genomic data, explains DOC relevance, and includes validation of findings or a new analytic method.

Who should skip this route?

Skip it if the project lacks genomic-data analysis, lacks DOC relevance, or depends mainly on new data collection.

Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.